[1] 夏志颖,颜丽芬,梁长虹. 增强CT与MRI多期增强扫描对小肝癌诊断价值比较[J]. 中西医结合肝病杂志, 2024, 34(7): 624-626. DOI:10.3969/j.issn.1005-0264.2024.007.010.
[2] 郭大鹏,李汝锐,靳仓正. 能谱CT成像在小肝癌诊断及鉴别诊断中的价值[J]. 中国CT和MRI杂志, 2023, 21(6): 110-112. DOI:10.3969/j.issn.1672-5131.2023.06.036.
[3] Chaudhary U, Desai PA, Takahashi N, et al. Automated detection and segmentation of small cell lung cancer liver metastases on CT[J]. J Clin Oncol, 2022, 40(16): e13555. DOI:10.1200/JCO.2022.40.16_suppl.e13555.
[4] 麻红娟,张天赐,钟玉琴. 超声造影联合MSCT诊断肝硬化合并小肝癌的价值[J]. 国际医药卫生导报, 2024, 30(23): 3967-3972. DOI:10.3760/cma.j.issn.1007-1245.2024.23.017.
[5] 王健庄,崔创撑. CT引导下125I粒子植入联合TACE+射频消融治疗肝包膜下小肝癌的价值[J]. 中国CT和MRI杂志, 2024, 22(2): 111-113. DOI:10.3969/j.issn.1672-5131.2024.02.035.
[6] 郭大鹏,龙仲云,胡海菁. CT能谱成像结合AFP、GP73及GPC-3检测对小肝癌的诊断价值[J]. 分子诊断与治疗杂志, 2023, 15(4): 581-584. DOI:10.3969/j.issn.1674-6929.2023.04.010.
[7] Maeda Y, Kobashi K, Sato Y, et al. Effectiveness of CT-image guidance in proton therapy for liver cancer and the importance of daily dose monitoring for tumors and organs at risk[J]. Med Phys, 2023, 50(6): 3274-3288. DOI:10.1002/mp.16433.
[8] 谢慧,王亮亮,江凯,等. 多层螺旋CT与高场强磁共振LAVA增强对乙型肝炎肝硬化背景小肝癌的诊断价值对比[J]. 肝脏, 2022, 27(8): 895-897,907. DOI:10.3969/j.issn.1008-1704.2022.08.018.
[9] 邢艳虎,黄忠江,侯跃宏. 基于增强CT影像组学鉴别小肝癌与肝不典型增生结节的应用研究[J]. 中国CT和MRI杂志, 2023, 21(7): 107-109. DOI:10.3969/j.issn.1672-5131.2023.07.036.
[10] Qiu YD, Yan Q, Wang Y, et al. Discovery of a selective TRF2 inhibitor FKB04 induced telomere shortening and senescence in liver cancer cells[J]. Acta Pharmacol Sin, 2024, 45(6): 1276-1286. DOI:10.1038/s41401-024-01243-6.
[11] 李艳红,王芳,杨小英,等. MSCT对乙肝肝硬化再生结节与小肝癌的鉴别诊断价值[J]. 中国医疗设备, 2022, 37(12): 77-81. DOI:10.3969/j.issn.1674-1633.2022.12.015.
[12] 徐晓莉,张涛,张学琴. 肝硬化患者出血后多发再生结节梗死的CT和MRI表现[J]. CT理论与应用研究, 2023, 32(4): 539-544. DOI:10.15953/j.ctta.2022.063.
[13] 刘新爱,任月勤. 应用DCE-MSCT扫描鉴别诊断小肝癌及肝硬化再生结节的可行性研究[J]. 中国CT和MRI杂志, 2022, 20(3): 77-79. DOI:10.3969/j.issn.1672-5131.2022.03.025.
[14] Xie C, Peng Y, Zhang Z, et al. Tumor microenvironment activatable nanoprodrug system for in situ fluorescence imaging and therapy of liver cancer[J]. Anal Chem, 2024, 96(12): 5006-5013. DOI:10.1021/acs.analchem.4c00317.
[15] 宋文月,耿承军,江凯. T2WI序列图像与多期多排螺旋CT扫描对肝硬化患者结节和小肝癌的鉴别诊断价值[J]. 肝脏, 2022, 27(6): 644-646,667. DOI:10.3969/j.issn.1008-1704.2022.06.010.
[16] 谢卫东,王健,李扬. MRI多b值成像联合低剂量多层螺旋CT扫描对肝硬化再生结节与小肝癌结节的鉴别诊断价值[J]. 实用癌症杂志, 2022, 37(9): 1503-1507. DOI:10.3969/j.issn.1001-5930.2022.09.028.
[17] Zhu L, Yu X, Tang X, et al. Evolving landscape of treatments targeting the microenvironment of liver metastases in non-small cell lung cancer[J]. Chin Med J (Engl), 2024, 137(9): 1019-1032. DOI:10.1097/CM9.0000000000002981.
[18] 吕沙沙,郑静,牛忠锋. 能谱CT鉴别直径≤3cm肝硬化结节和小肝癌[J]. 实用放射学杂志, 2023, 39(7): 1119-1122. DOI:10.3969/j.issn.1002-1671.2023.07.017.
[19] 杨挺,马小燕,龙光华. MR多序列检查在CT等密度小肝癌中的临床应用价值研究[J]. 贵州医药, 2022, 46(5): 805-807. DOI:10.3969/j.issn.1000-744X.2022.05.074.
[20] Liu X, Tan SBM, Awiwi MO, et al. Imaging findings in cirrhotic liver: pearls and pitfalls for diagnosis of focal benign and malignant lesions[J]. Radiographics, 2023, 43(9): e230043. DOI:10.1148/rg.230043.
[21] Cao J, Shon A, Yoon L, et al. Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease[J].Eur Radiol, 2024, 34(12): 7622-7631. DOI:10.1007/s00330-024-10846-w.
[22] 郭小芳,王凌云,吕天宝.CT扫描结合MRI在原发性肝癌诊断与介入治疗预后评估中的临床意义[J].广州医药,2022,53(1):58-61.DOI:10.3969/j.issn.1000-8535.2022.01.012.
|